SNWV is on high alert. Trading at $0.20 w/ a $0.55 valuation +

=====================
SNWV (SANUWAVE Health, Inc.)

Float: 44.01M

Alert Price: $0.205

Valuation: $0.55
(Zacks Small-Cap Research)

Chart Analysis

Investor Presentation

Website | Recent News
========================


Members,

Earlier today we promised to a bring you an up-and-coming biotech company that has the potential to double its share price in the immediate future.

So without further ado, we ask that you turn your immediate attention to SNWV (SANUWAVE Health Inc.).
Health care is big business, and researchers are always working on the next big treatment option that will revolutionize the industry. One area that doesn’t get much attention despite having a big need is the treatment of diabetic foot ulcers (DFUs), where SNWV has been focusing its efforts. Diabetes is a horrible disease, and especially as we continue to see the demographics of many countries get older, this is going to be a larger and growing market in the years to come.

With a market cap of less than $30 million, SNWV is still relatively small and unknown, but we have a feeling that is going to change very soon…

We see significant growth opportunities available for the SNWV thanks to the cutting edge technological advancements they have made thus far.

Why their Technology is so Special

SNWV has developed a technology that utilizes high-energy acoustic shock waves to help restore the natural healing process. Pulsed Acoustic Cellular Expression (PACE) is both proprietary and patented by Sanuwave, and is the prized technology that helps repair tissues and allows them to regenerate.

Currently, patients with DFU simply have their wounds cleaned and are bandaged back up. With this technology, the wound can heal and improve both the quality of life for a patient and increase their lifespan. DFUs can end up leading to amputation and 65% of patients die within five years.

SNWV currently has two products in their pipeline that could be lifesavers for patients in this multi-billion dollar market!

dermaPACE, the company’s flagship device, is already FDA-approved in the US for treating DFUs, and has passed European standards for a CE marked device as well. The device has experienced growing demand into other parts of the world, and could see an even larger growth in demand as it becomes available to more patients.

orthoPace, while not yet FDA-approved, is also a CE Marked device passing European standards. Both of these products utilize the PACE technology.

SNWV has an All-Star CEO

Kevin Richardson is the CEO of Sanuwave, and he’s got a good track record when it comes to health care. He previously developed “The Vac,” which is used for Negative Pressure Wound Therapy. The company that owned the product, Kinetic Concepts, went on to generate over $1 billion in revenue, and was ultimately taken private for around $11.5 billion.

Sanuwave is nowhere near that value today, but with the guidance of its CEO, there’s a lot of hope that it could achieve similar success. Richardson has demonstrated an eye for value and opportunity, and his leadership ability will certainly help grow Sanuwave’s brand.

SNWV Reports Record 2018 Financial Results

SNWV witnessed revenue growth of +151% in 2018!

The increase in revenue for 2018 was primarily due to initial sales of dermaPACE devices in the United States, an increase in sales of orthoPACE devices in Asia/Pacific and the European Community, as compared to the prior year, as well as higher sales of new applicators.

2018 was filled with achievements meant to prepare SANUWAVE for rapid revenue growth beginning in 2019 and beyond. The stage is set and it is now dependent on our ability to execute the well developed plan of placing 100 dermaPACE devices in the US in 2019. Our vision is to be viewed by the world as a diverse, compassionate global family that provides positive impact on life and environment, one shock at a time. The goal for SANUWAVE remains unchanged and that is to have a dermaPACE device anywhere and everywhere a DFU is treated.

SNWV's Bullish Outlook for 2019

Sanuwave saw strong growth in 2018 and it expects 2019 to be even better, with device sales expected to reach 120 units.

In five years, Sanuwave hopes to have as many as 2,000 placements and expects revenues to reach over $100 million. Additionally, the company is looking to continuing to build on its international presence this year as it hopes to expand into three to four more countries.

There you have it, SNWV appears to be a clear cut winner from head to toe.

The Company has:

Strong Revenue Growth
Innovative Products
FDA Approval
Seasoned Management Team
A valuation that is +175% above its current share price
Bullish Outlook for 2019
It's no surprise why we think SNWV's share price could double in the very near future.

That being said, we suggest that you start your research now, and add SNWV to the top of your watchlist.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia, and New Zealand. In the U.S., dermaPACE®, is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food, and industrial markets.

Company Highlights & Recent Developments

Accomplishments in 2018

Hired Shri Parikh, President Healthcare
Received reimbursement tracking for DFU procedure
Signed Premier Shockwave as the exclusive distributor for the VA and IHS
Added Science Advisor, Dr. Perry Mayer
JWC published a peer review article on SANUWAVE’s 336 double blind study
Added 15 countries to international distribution
Signed with NFS to help finance equipment growth
Goals for 2019

100 US Placements ; 300 certified users
Reimbursement; finish with at least 10 million covered lives
Launch 2-3 domestic clinical studies
Add 3-4 new countries
Add Additional science advisors
Add other key senior management hires
To help facilitate its growth, Sanuwave partnered with Premier Shockwave, Inc., a leader for shockwave treatments used for podiatric and orthopedic applications.
By working with Premier Shockwave, Inc., Sanuwave has been able to gain access into key markets in the United States, such as:

Veteran’s Administration (VA)
Indian Health Services (IHS)
Tribally Operated Healthcare Services
US Military Treatment Facilities (MTFs)
Currently, Premier Shockwave serves and has access to more than 30 VA hospitals and MTFs.

We expect another record breaking year for SNWV

During the past year, the company hit record sales numbers and expanded into 15 new countries via partnerships, which could make this year even better. However, Sanuwave is not stopping there. It’s continuing on plans for international expansion, and it expects shipments to hit a new record in 2019. Find out which countries and regions are key to Sanuwave’s international growth by signing up for our exclusive report.

Sanuwave is also continuing to conduct clinical studies, with between two and three planned for the U.S. to help with the rollout of its products. It’s also working with insurance providers to get reimbursement coverage, which would undoubtedly lead to more adoption of its products, and help grow sales even more.

Sanuwave is an exciting young company that’s still in its early-growth stages. With great products that solve a big problem in a big market, it has all the ingredients for significant and rapid growth.

Recent Developments

SANUWAVE Receives U.S. and European Patents for Intracorporeal Shockwave Systems for Treating Blood Vessels in Cardiology and Endovascular Fields

SUWANEE, GA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, received United States Patent US 10,238,405 on March 26, 2019 entitled “Blood Vessel Treatment with Intracorporeal Pressure Shock Waves” which has a patent life up to January 2032 from the U.S. Patent and Trademark Office (USPTO). This U.S. patent includes eight (8) claims related to the special construction of the intracorporeal shockwave apparatuses/systems comprising of a catheter size fit within a blood vessel, with one or multiple shockwave applicators that include shockwave generation sources disposed within an ellipsoidal reflector oriented perpendicular to the catheter longitudinal central axis of symmetry, which can produce focused shockwaves oriented towards vessel’s wall where the plaques are forming. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric.

Also, SANUWAVE received European Patent EP 3,117,784 on December 26, 2018 entitled “Usage of Intracorporeal Pressure Shock Waves in Medicine”, which has an expiration date in July 2030 from the European Patent Office (EPO). This patent is validated in designated countries including Denmark, Finland, France, Germany, Great Britain, Holland, Ireland, Italy, Norway, Spain, and Sweden. The European patent includes fifteen (15) claims related to the special construction of the intracorporeal shockwave devices/systems comprising of a catheter size fit within at least one of a blood vessel, graft, or artificial blood vessel, with at least one balloon, and at least one or multiple shockwave generation sources coupled to the catheter. The intracorporeal shockwave device/system can be used to treat plaques and obstructions together with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric.

The use of intracorporeal shockwave systems can constitute a new therapy option in treating cardiovascular or endovascular arterial systems for partial obstructions due to atherosclerotic plaques or vulnerable plaques. The intracorporeal shockwave systems described in these patents can be used to treat blood vessels’ plaques and partial obstructions in conjunction with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain, which can possess significant health hazard for the patient. Such intracorporeal shockwave systems can be also used to promote accelerated healing after angioplasty or stenting using metal bare stents or drug eluting stents; or to treat in-stent restenosis.

“We have an extensive and growing Intellectual Property (IP) portfolio. It will make sense to maintain and grow some of the IP portfolio on our own as we develop our wound business. For other non-medical and various medical markets, we prefer to find good corporate partners, possibly in the atherosclerotic, cardiology, or endovascular space to bring the IP to a commercial stage. We plan to pursue monetization and partnering of our IP portfolio on a selective basis and will engage with vetted partners before the end of the year,” commented Kevin A. Richardson, II, CEO and Chairman of the Board at SANUWAVE.

SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 52 medical patents (issued or pending) and 22 non-medical patents (issued or pending) related to shockwave technology.

Market Outlook

The Market Could Potentially Hit Close to $50Billion by 2024

In the United States, as many as 1.9 million new cases of DFU are diagnosed every year. And in five years, it’s estimated that the market for DFU and pressure ulcers will potentially reach $4.9 billion. It’s a big industry that is in direct need of improved treatment options, and Sanuwave could help fill that void.

Market Opportunity with The dermaPACE® System

U.S Market

Diabetic Foot Ulcers - $4B+ market size.
29 million people living with diabetes and 86 million pre-diabetics.
25% of diabetics will acquire a non-healing ulcer in their lifetime; ~3 million diabetic ulcers annually.
Diabetic foot ulcers lead to over 50,000 amputations annually at a cost that is estimated to exceed $5.1billion annually.
Hospitalization costs of ~$20,000 for a patient with a DFU; ~$70,000 for an amputation.
International Market

Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%.
dermaPACE is CE Marked and currently marketed by independent distributors in Canada, Romania, Italy, S. Korea, Taiwan, Malaysia and Indonesia.
dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs.
Other Industries Could Unlock More Opportunities Including Licensing and Partnerships

What makes the PACE technology even more valuable is that it isn’t limited to just health care. It has been patented for other uses as well, and can be used in energy, water, food, and industrial effluent markets. With so many different ways the technology can be utilized, it could open up a lot of different doors, and potentially attract the interest of big companies in other industries.

Technical Analysis

Based on our very own chart analysis we see very little downside risk, and an upside that almost looks too good to ignore.

There is the potential for a move of over +50% in the near future.

SNWV is currently trading at the lower end of its 52-week price channel.

Less than a year ago, shares of SNWV were trading at over $0.60.

A run back to those levels would show our members gains of over +200%!

The float on SNWV is fairly thin at 40M, and we all know how fast these biotech stocks can move...

We believe that SNWV could be our next trade alert to double in price!

As such we are urging our members to start their research now, add it to the top of their watchlist, and consider grabbing a piece of SNWV tomorrow morning at 9:30AM EST.

(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)



Best Regards,


The PennyStock101 Team


Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.

Msg&data rates may apply.)





DISCLAIMER

This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.



MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources to conduct investor relations advertising and marketing for SNWV. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.


We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.